FGEN - FibroGen Inc

-

$undefined

N/A

(N/A)

FibroGen Inc NasdaqGS:FGEN FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Location: 350 Bay Street, San Francisco, CA, 94133, United States | Website: https://www.fibrogen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

131.7M

Cash

33.61M

Avg Qtr Burn

-19.0M

Short % of Float

5.14%

Insider Ownership

1.72%

Institutional Own.

33.02%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Roxadustat (ROW) Details
Chronic kidney disease, Anemia

Approved

Quarterly sales

Roxadustat Details
Chemotherapy Induced Anemia

PDUFA

Approval decision

Roxadustat Details
Myelodysplastic syndrome, Anemia

Phase 3

Update

FG-3246 (ADC) Details
Cancer, Castration-resistant prostate cancer

Phase 2

Initiation

FG-3246+ enzalutamide Details
Cancer, Castration-resistant prostate cancer

Phase 1/2

Data readout

FG-3165 Details
Cancer, Solid tumor/s

Phase 1

Initiation

Pamrevlumab Details
Cancer, Pancreatic cancer

Failed

Discontinued

Pamrevlumab Details
Pancreatic cancer, Cancer

Failed

Discontinued

Roxadustat (U.S.) Details
Anemia, Chronic kidney disease

Failed

Discontinued

Pamrevlumab Details
Idiopathic pulmonary fibrosis

Failed

Discontinued

Pamrevlumab Details
Duchenne muscular dystrophy

Failed

Discontinued

Pamrevlumab Details
COVID-19, Infectious disease

Failed

Discontinued